Moreover, the 36-month beta value for NXTC is 0.63. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NXTC is 21.32M and currently, short sellers hold a 0.24% of that float. On December 26, 2024, NXTC’s average trading volume was 93.14K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NXTC) stock’s latest price update
Nextcure Inc (NASDAQ: NXTC)’s stock price has dropped by -7.76 in relation to previous closing price of 0.94. Nevertheless, the company has seen a gain of 2.85% in its stock price over the last five trading days. globenewswire.com reported 2024-12-10 that LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences
NXTC’s Market Performance
Nextcure Inc (NXTC) has seen a 2.85% rise in stock performance for the week, with a -22.15% decline in the past month and a -32.38% plunge in the past quarter. The volatility ratio for the week is 9.90%, and the volatility levels for the past 30 days are at 9.00% for NXTC. The simple moving average for the past 20 days is -18.72% for NXTC’s stock, with a -41.64% simple moving average for the past 200 days.
Analysts’ Opinion of NXTC
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see NXTC reach a price target of $16. The rating they have provided for NXTC stocks is “Buy” according to the report published on March 01st, 2022.
Truist gave a rating of “Buy” to NXTC, setting the target price at $19 in the report published on March 05th of the previous year.
NXTC Trading at -29.71% from the 50-Day Moving Average
After a stumble in the market that brought NXTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.23% of loss for the given period.
Volatility was left at 9.00%, however, over the last 30 days, the volatility rate increased by 9.90%, as shares sank -27.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.00% lower at present.
During the last 5 trading sessions, NXTC fell by -3.63%, which changed the moving average for the period of 200-days by -44.36% in comparison to the 20-day moving average, which settled at $1.0650. In addition, Nextcure Inc saw -18.74% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NXTC
Current profitability levels for the company are sitting at:
- -9.63 for the present operating margin
- 0.61 for the gross margin
The net margin for Nextcure Inc stands at -9.31. The total capital return value is set at -0.74. Equity return is now at value -57.93, with -50.82 for asset returns.
Currently, EBITDA for the company is -59.04 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.07.
Conclusion
To wrap up, the performance of Nextcure Inc (NXTC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
